New drug combo shows promise in shrinking esophageal tumors before surgery
NCT ID NCT07430579
First seen Feb 28, 2026 · Last updated Jun 18, 2026 · Updated 21 times
Summary
This study tests whether adding the drug adebrelimab to standard chemotherapy before surgery can help eliminate or shrink esophageal cancer more effectively. About 25 people with stage II/III esophageal squamous cell carcinoma will receive the combination, then have surgery. Researchers will check how many have no cancer left after treatment and monitor side effects and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for QUALITY OF LIFE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Qilu Hospital of Shandong University
RECRUITINGJinan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.